The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2010-01-01 / J. Virol. 2010 Jan;84(1):639-46Oncolytic virus therapy for prostate cancer
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-84Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21Cutting Edge: TLR-Dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells
/in International Publications, Newcastle Disease Virus /von 2009-04-01 / J. Immunol. 2009 Apr;182(7):3960-4Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62Genetically engineered Newcastle disease virus for malignant melanoma therapy
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2009-02-26 / Gene Ther. 2009 Jun;16(6):796-804
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de